OK PSA - liposomal

Drug Profile

OK PSA - liposomal

Alternative Names: Lipo-OK PSA; Liposomal picibanil derivative; OK-PSA

Latest Information Update: 19 Sep 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chugai Pharmaceutical
  • Class Antineoplastics; Polysaccharides
  • Mechanism of Action Toll-like receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 19 Sep 2006 Discontinued - Phase-I for Cancer in Japan (unspecified route)
  • 15 Dec 2003 A study has been added to the Cancer pharmacodynamics section
  • 19 Feb 2003 Phase-I clinical trials in Cancer in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top